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Abstract
Objective To determine whether use of serotonin or non-serotonin
reuptake inhibitors near to delivery is associated with postpartum
hemorrhage.
Design Cohort study.
Setting 2000-07 nationwide Medicaid data (Medicaid Analytic eXtract).
Population 106 000 pregnant women aged 12-55 with a diagnosis of
mood or anxiety disorder. Women were categorized into four mutually
exclusive exposure groups according to pharmacy dispensing data:
current (delivery date), recent (1-30 days before delivery date), past (1-5
months before delivery date), and no exposure (reference group).
Main outcome measures Risk of postpartum hemorrhage by timing of
exposure and by serotonin or non-serotonin reuptake inhibitors, classes
of antidepressant, and antidepressant types. Relative risks and 95%
confidence intervals adjusted for delivery year, risk factors for postpartum
hemorrhage, indicators of severity of mood/anxiety disorder, other
indications for antidepressants, and other drugs. High dimensional
propensity score (hdPS) methods were used to empirically identify and
adjust for additional factors.
Results 12 710 (12%) women had current exposure to serotonin
reuptake inhibitor monotherapy, and 1495 (1.4%) women had current
exposure to non-serotonin reuptake inhibitor monotherapy. The risk of
postpartum hemorrhage was 2.8% among women with mood/anxiety
disorders but no exposure to antidepressants, 4.0% in the current users
of serotonin reuptake inhibitors, 3.8% in the current users of
non-serotonin reuptake inhibitors, 3.2% in the recent users of serotonin
reuptake inhibitors, 3.1% in the recent users of non-serotonin reuptake
inhibitors, 2.5% in the past users of serotonin reuptake inhibitors, and
3.4% in the past users of non-serotonin reuptake inhibitors. Compared
with no exposure, women with current exposure to serotonin reuptake
inhibitors had a 1.47-fold increased risk of postpartum hemorrhage (95%
confidence interval 1.33 to 1.62) and women with current non-serotonin
reuptake inhibitor exposure had a 1.39-fold increased risk (1.07 to 1.81).
Results were similar with hdPS adjustment.Womenwith current exposure
to serotonin reuptake inhibitors had an adjusted excess risk of 1.26%
(0.90% to 1.62%), with a number needed to harm of 80, and for women
with current exposure to non-serotonin reuptake inhibitors the excess
risk was 1.03% (0.07% to 1.99%), with a number needed to harm of 97.
For exposure to serotonin reuptake inhibitors the relative risk was 1.19
(1.03 to 1.38) for recent exposure and 0.93 (0.82 to 1.06) for past
exposure; for non-serotonin reuptake inhibitors the figures were 1.17
(0.80 to 1.70) and 1.26 (1.00 to 1.59), respectively. Current exposure to
selective serotonin reuptake inhibitor monotherapy was also associated
with postpartum hemorrhage (1.42, 1.27 to 1.57), as was current
serotonin norepinephrine (noradrenaline) reuptake inhibitor (1.90, 1.37
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to 2.63) and tricyclic monotherapy (1.77, 0.90 to 3.47). All types of
selective serotonin reuptake inhibitors available for analysis and
venlafaxine, a serotonin norepinephrine reuptake inhibitor, were
significantly associated with postpartum hemorrhage.
Conclusions Exposure to serotonin and non-serotonin reuptake
inhibitors, including selective serotonin reuptake inhibitors,
serotonin-norepinephrine reuptake inhibitors, and tricyclics, close to the
time of delivery was associated with a 1.4 to 1.9-fold increased risk for
postpartum hemorrhage. While potential confounding by unmeasured
factors cannot be ruled out, these findings suggest that patients treated
with antidepressants during late pregnancy are more likely to experience
postpartum hemorrhage.
Introduction
Postpartum hemorrhage is a leading cause of maternal mortality
in the United States and elsewhere1 2 and is a substantial
contributor to severe maternal morbidity, blood transfusions,
and admissions to intensive care.3 4 The incidence of postpartum
hemorrhage has increased since the 1990s in the US (from 2.3%
to 2.9% between 1994-2006)5 and in several other developed
countries.6-8 This trend is not fully explained by temporal
changes in the frequency of established risk factors for
postpartum hemorrhage, including multiple pregnancy and
induction and/or augmentation of labor.6 7 As postpartum
hemorrhage is serious, the causes of this increase in incidence
need to be identified.
Many, but not all, studies have shown that use of antidepressants
that inhibit serotonin reuptake increase the risk of bleeding
events, such as gastrointestinal and perioperative bleeding.9-14
Use of serotonin reuptake inhibitors is thought to increase risk
of bleeding by depleting platelet serotonin.15 Between 7-13%
of pregnant women in the US are treated with antidepressants.16-18
Only two studies, both in non-US populations, however, have
investigated the association between antidepressants and
postpartum hemorrhage. Salkeld and colleagues reported a
1.30-fold borderline significant increased risk of postpartum
hemorrhage associated with use of a selective serotonin reuptake
inhibitors in the 90 days before delivery,19 and Reis and
colleagues reported a 1.45-fold increased risk for bleeding
during delivery in a comparison of any versus no use of
antidepressants.20 While these studies raise concerns, they had
limitations including potential confounding by mood disorders
or factors associated with them, exposure windows that did not
focus on delivery, and limited power to assess specific
antidepressants.
Medicaid is the joint state and federal health insurance program
for low income individuals in the US. Using nationwide
Medicaid data, we assessed the association between exposure
to antidepressants at the time of delivery and postpartum
hemorrhage.We hypothesized that women exposed to serotonin
reuptake inhibitors at the time of delivery would have an
increased risk compared with those without any exposure, while
women with serotonin reuptake inhibitor exposure only well
before delivery and women exposed to non-serotonin reuptake
inhibitors antidepressants would not have an increased risk.We
accounted for the potential effect of underlying mood/anxiety
disorders, considered exposure at the time of delivery (the likely
relevant exposure period), classified antidepressant use
according to serotonin transporter affinity, and evaluated risk
of postpartum hemorrhage with respect to specific classes and
types of antidepressants.
Methods
Eligible population
We previously identified a cohort of pregnancies ending in live
birth in 2000-07Medicaid Analytic eXtract (MAX) data among
women aged 12-55.21-23 To ensure claim completeness during
the second half of the pregnancy, women were required to have
Medicaid enrollment and meet eligibility criteria—that is, no
private insurance, no restricted benefits, and appropriate type
of enrollment from five months before delivery until after
delivery. The eligible population included 2 759 414 pregnancies
from 2 340 631 women.
Mood and anxiety disorders
We restricted the primary analyses to a subcohort of 106 000
women with diagnoses for mood or anxiety disorders (as
inpatients or outpatients; ICD-9 (international classification of
diseases, ninth revision) code for 296.x, 300.x, 309.x, or 311.x)
between one and five months before delivery (fig 1⇓) to reduce
the potential for confounding by unmeasured factors that are
correlated with these disorders. The positive predictive value
for depression with these codes was 77%,24 indicating that most
women in this subcohort likely had depression. We restricted
a secondary analysis to women with diagnostic codes specific
for depression—that is, those that did not include bipolar and
anxiety disorders (ICD-9 codes: 296.2x, 296.3x, 296.9, 300.4x,
309.0x, 309.1x, 309.28, 311.x).
Outcome
Women with an ICD-9 code for 666.x during the admission to
hospital for delivery, or within three days after the delivery date
for outpatient deliveries, were classified as having postpartum
hemorrhage.We also considered atonic postpartum hemorrhage
only (666.1x; caused by inadequate uterine contraction)25 and
inpatient postpartum hemorrhage only.
Exposure
Most antidepressants are inactivated and eliminated within days
to a week after use,26 yet the potential carry over effect on the
risk of postpartum hemorrhage after discontinuation of is
unknown. Consequently, we defined four mutually exclusive
exposure groups based on the dispensing date of prescription
and days’ supply dispensed relative to the delivery date:
• Current exposure: womenwith a supply of antidepressants
that overlapped with the delivery date
• Recent exposure: women with a supply of antidepressants
on at least one day in the month before the delivery date
but not on the delivery date
• Past exposure: women with a supply of antidepressants
ending between five and one months before delivery
• Unexposed: women who had no supply of antidepressants
in the five months before delivery (reference group).
Because the degree of inhibition of serotonin reuptake is thought
to play a role in the association between antidepressants and
abnormal bleeding events,9 10 13 14 we classified the exposure
groups by serotonin transporter affinity with previously reported
serotonin transporter dissociation constants (Kd)27-29; a lower
Kd reflects a higher affinity for the serotonin transporter.
Antidepressants with serotonin transporter Kd 0-9.9 nM were
classified as serotonin reuptake inhibitors and antidepressants
with Kd ≥10 nM were classified as non-serotonin reuptake
inhibitors (appendix 1). We considered only monotherapy with
either type and therefore excluded from the primary analysis
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the 3278 women who were exposed to both drugs types
(polytherapy) during the five months before delivery.
We considered also current, recent, and past exposure to specific
antidepressants if at least 100 women with mood/anxiety
disorders and current serotonin or non-serotonin reuptake
inhibitor monotherapy were exposed to a given drug. Next we
considered exposure to any antidepressant. We then defined
exposure groups by class (appendix 1): selective serotonin
reuptake inhibitor, serotonin norepinephrine (noradrenaline)
inhibitor, tricyclic, bupropion, and other antidepressants,
excluding from this analysis women exposed to more than one
class.
Covariates
Baseline information on comorbidities and healthcare use was
obtained from data between one and fivemonths before delivery,
before the recent and current exposure windows. Potential
confounders included risk factors for postpartum
hemorrhage6 25 30 31: delivery year, age (as a quadratic spline),
race, multiple pregnancy, coagulopathies, diabetes (classified
as diagnosis and no dispensing of antidiabetic drugs, no
diagnosis but with dispensing, diagnosis and dispensing); proxies
of mood/anxiety disorder severity (number of outpatient (0, 1,
2-5, 6-9, ≥10) and inpatient (0, 1, ≥2) diagnoses of mood/anxiety
disorder); other indications for antidepressants (psychotic
disorder, other mental health disorder, pain related diagnoses);
use of other psychotropic drugs (anticonvulsants and
benzodiazepines); other drugs associated with risk of bleeding
(aspirin, heparin, and warfarin); and proxies of comorbidity
(number of outpatient visits (quadratic spline) and days in
hospital (0, 1-2, 3-4, 5-6, ≥7)).32 Potential mediators of
postpartum hemorrhage—that is, risk factors that could be
affected by antidepressant use and consequently would not be
confounders33—included delivery characteristics (short labor,
long labor, forceps or vacuum delivery, or induced labor6 7 25 30 31)
as documented during the admission for delivery or within three
days after the delivery date for outpatient deliveries.
Statistical analysis
We compared the risk for postpartum hemorrhage between
women with exposure to antidepressants and the unexposed
group using relative risks and risk differences and their
corresponding 95% confidence intervals from generalized
estimating equations.34 35 Models were adjusted for potential
confounders and robust variances were used to account for
correlations among multiple pregnancies in the same woman.35
Furthermore, we used high dimensional propensity score (hdPS)
methods to empirically identify and adjust for additional factors
that might be surrogates for unmeasured confounders in the
databases.36 37 We excluded 2.5% of women on both extremes
of the distribution of the propensity score and adjusted logistic
regression models for 10ths of the score, which was estimated
from investigator defined covariates and 200 empirically
identified variables. To support the validity of our outcome
definition, we also assessed the association between well
established risk factors for postpartum hemorrhage and
occurrence of postpartum hemorrhage. Because women in this
cohort were younger and more racially diverse than those in
previous studies,19 20 we tested for multiplicative effect
modification of current exposure by age (≥30) and race/ethnicity
(white and non-white). To determine if there was an indirect
effect of current exposure to serotonin or non-serotonin reuptake
inhibitors on postpartum hemorrhage through any of the
measured delivery characteristics that are risk factors for
postpartum hemorrhage, we performed a mediation analysis38 39
using estimates from logistic regression models for postpartum
hemorrhage and for the delivery characteristics. All analyses
were conducted with SAS software, version 9.2 for Windows
(SAS Institute, Cary, NC).
Sensitivity analyses
We performed eight sensitivity analyses to evaluate the
robustness of the results. Because obesity is associated with
postpartum hemorrhage and is poorly measured by healthcare
use data, we conducted a sensitivity analysis40 41 to correct the
relative risks for current use of serotonin and non-serotonin
reuptake inhibitors for confounding by unmeasured obesity.
Using data for women aged 18-55 with depression from the
2005-10 National Health and Nutrition Examination Survey
(NHANES), we estimated the prevalence for obesity among
those women who reported antidepressant use and those who
reported no antidepressant use, accounting for the complex
sampling design.42 We assumed the relative risks for obesity
and postpartum hemorrhage was between 1.5 and 2.0 for the
obesity correction.43 44 Second, we repeated the primary analysis
but included all womenwith andwithout mood/anxiety disorders
(n=2 759 414 pregnancies). Third, we restricted the study
population to the 1 248 875 (45.3% of the overall study
population) women who met requirements for Medicaid
enrollment and eligibility throughout pregnancy; baseline
covariates were assessed with data between one month and nine
months before delivery and the past exposure window began at
nine months before delivery. Fourth, we restricted the cohort
with mood/anxiety disorder diagnoses to women without a
diagnosis of hypertension or use of antihypertensive drugs.
While hypertension is a risk factor for postpartum
hemorrhage,7 31 increased blood pressure can be a consequence
of using certain antidepressants45 46 so we avoided stratification
by hypertension in the primary analysis.47 Fifth, in a dose
analysis, we categorized women with current serotonin and
non-serotonin reuptake inhibitor monotherapy according to the
highest antidepressant dose that overlapped with the delivery
date and compared them with women without exposure to
antidepressants. Dose levels were defined according toGoodman
and Gilman’s usual dose (mg/day)26: low is less than the lowest
usual dose, medium is less than or equal to the midpoint of the
usual dose range, high is more than the midpoint of the usual
dose range (appendix 1). Because of small numbers, we
combined medium and high doses for non-serotonin reuptake
inhibitors. Sixth, we considered users of polytherapy in each
exposure window—that is, women with current exposure to
both serotonin and non-serotonin reuptake inhibitors—and
determined their risk of postpartum hemorrhage compared with
unexposed women. Seventh, we restricted the current exposure
group to women who likely had the highest adherence—that is,
those with exposure to the drug on more than 75% of days
during the three months before delivery. Finally, in an exposure
sensitivity analysis, we classified women with an antidepressant
dispensed less than 14 days before delivery, regardless of days
of supply on the delivery date, as having current exposure.
Results
Among pregnant women with mood/anxiety disorders, 15.1%
had a supply of antidepressants that overlapped their delivery
date. There were 12 710 (12%) women with current exposure
to serotonin reuptake inhibitor monotherapy and 1495 (1.4%)
womenwith current exposure to non-serotonin reuptake inhibitor
monotherapy. Compared with unexposed women, more women
in the exposed groups were older and white and had
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hypertension, admission to hospital with a diagnosis of
anxiety/mood disorders, other antidepressant indications, and
other psychotropic drugs (table 1⇓). There were, however, fewer
differences in patients between groups defined by current, recent,
and past exposures to serotonin and non-serotonin reuptake
inhibitors. Overall, 91% of women delivered in a hospital.
Among women who delivered in a hospital, 69% delivered on
the admission date and 95% delivered within one day of being
admitted.
The risk of postpartum hemorrhage was 2.4% among women
without diagnoses of mood/anxiety disorder and without
exposure to antidepressants in the five months before delivery
and 2.8% among women with mood/anxiety disorders but
without exposure to antidepressants. The risk of postpartum
hemorrhage was 4.0% in current users of serotonin reuptake
inhibitors and 3.8% in current users of non-serotonin reuptake
inhibitors; for recent users the risk was 3.2% and 3.1%,
respectively, and for past users risk was 2.5% and 3.4%,
respectively. Compared with women without each predisposing
factor, women with pre-eclampsia (relative risk 1.43, 95%
confidence interval 1.26 to 1.64), labor induction (1.56, 1.42 to
1.72), and forceps or vacuum delivery (1.39, 1.21 to 1.59) had
an increased risk for postpartum hemorrhage. After adjustment
for potential confounders, compared with unexposed women,
current users of a serotonin reuptake inhibitor had a 1.47-fold
increased risk for postpartum hemorrhage (95% confidence
interval 1.33 to 1.62) and the current non-serotonin reuptake
inhibitor monotherapy group had a 1.39-fold increased risk
(1.07 to 1.81) (table 2⇓). In absolute terms, women with current
exposure to serotonin reuptake inhibitors had an adjusted excess
risk of 1.26% (0.90% to 1.62%), with a number needed to harm
of 80; the figure for women with current non-serotonin reuptake
inhibitor exposure was 1.03% (0.07% to 1.99%), with a number
needed to harm of 97. Adjustment for additional potential
confounders through hdPS analysis yielded odds ratios of 1.52
(1.35 to 1.71) for current use of serotonin reuptake inhibitors
and 1.39 (1.03 to 1.89) for current use of non-serotonin reuptake
inhibitors (table 3⇓). For recent use of antidepressants, the
relative risk was 1.19 (1.03 to 1.38) for serotonin reuptake
inhibitor and 1.17 (0.80 to 1.70) for non-serotonin reuptake
inhibitor exposure. While the women with past exposure to
serotonin reuptake inhibitor monotherapy did not have an
increased risk for postpartum hemorrhage, in those with past
exposure to non-serotonin reuptake inhibitor monotherapy the
risk was slightly increased and nearly significant (table 2).⇓
The risk of postpartum hemorrhage was associated with current
exposure to specific serotonin reuptake inhibitor antidepressants,
the highest risk being with venlafaxine (table 4⇓). Compared
with unexposed women, women with current exposure to any
antidepressant had an increased risk for postpartum hemorrhage
(relative risk 1.44, 1.32 to 1.58), as did women with any recent
exposure (1.21, 1.06 to 1.38), while women with any past
exposure did not have an increased risk (table 5⇓). As a class,
current selective serotonin reuptake inhibitor monotherapy was
associated with postpartum hemorrhage (1.42, 1.27 to 1.57), as
was current serotonin norepinephrine reuptake inhibitor (1.90,
1.37 to 2.63) and tricyclic monotherapy (1.77, 0.90 to 3.47).
There was evidence of multiplicative effect modification by age
(P=0.02 for the exposure-age interaction term); there was no
association between current exposure to non-serotonin reuptake
inhibitor and postpartum hemorrhage among women aged at
least 30 (fig 2⇓ and appendix 2). None of the delivery
characteristics (short or long labor, instrumental delivery, labor
induction) were substantial mediators of the current associations
between serotonin or non-serotonin reuptake inhibitor and
postpartum hemorrhage.
External adjustment for obesity attenuated the relative risks to
between 1.3 and 1.4 for current serotonin reuptake inhibitors
and about 1.3 for current non-serotonin reuptake inhibitors. A
dose response was indicated for current exposure to serotonin
reuptake inhibitors but not for non-serotonin reuptake inhibitors
(table 6⇓). The relative risk was 1.42 (0.97 to 2.08) for current
polytherapy, 1.68 (0.94 to 3.00) for recent polytherapy, and 0.93
(0.60 to 1.44) for past polytherapy. All other sensitivity analysis
results are summarized in figure 2 (numbers and risks are listed
in appendix 2).⇓ The confidence intervals were wider for the
non-serotonin reuptake inhibitor than the serotonin reuptake
inhibitor groups. Past use of non-serotonin reuptake inhibitors
was not associated with postpartum hemorrhage in the cohort
of women both with and without diagnoses of mood/anxiety
disorder and the cohort of women who met eligibility criteria
throughout pregnancy and hadmood/anxiety disorders.Women
with the greatest amount of antidepressant coverage in the 90
days before delivery in the current serotonin reuptake inhibitor
exposure group had a 1.54-fold increased risk of postpartum
hemorrhage (95% confidence interval 1.36 to 1.76), and the
corresponding relative risk for the current non-serotonin
reuptake inhibitor exposure group was 1.25 (0.85 to 1.83). The
relative risks ranged from 1.32 to 1.54 in current users of
serotonin reuptake inhibitor monotherapy and from 1.31 to 1.69
for current users of non-serotonin reuptake inhibitor
monotherapy when we changed the exposure and outcome
definitions and when we restricted analysis to women with
depression and without hypertension.
Discussion
In this population of pregnant women, use of serotonin or
non-serotonin reuptake inhibitors at the time of delivery was
associated with about a 1.4 to 1.5-fold increase in risk of
postpartum hemorrhage and 1.0% to 1.3% excess risk. Selective
serotonin reuptake inhibitor, serotonin norepinephrine reuptake
inhibitor, and tricyclic monotherapy at the time of delivery were
associated with postpartum hemorrhage. Any exposure to
antidepressants in the month before delivery was associated
with about a 1.2-fold increased risk of postpartum hemorrhage.
While exposure to serotonin reuptake inhibitors one to five
months before delivery was not associated with postpartum
hemorrhage, exposure to non-serotonin reuptake inhibitors
during that time frame was associated with a nearly significant
increased risk.
Comparison with previous studies
The association we found between selective serotonin reuptake
inhibitor antidepressants and postpartum hemorrhage was
slightly higher than that reported by Salkeld and colleagues
from the Ontario administrative databases.19 Our exposure
window covered only the delivery date, whereas their primary
exposure window covered the 90 days before delivery. As
suggested by our analysis of recent exposure, their exposure
window could have been broader than the true exposure-risk
window, possibly leading to downward bias. Our estimates were
more precise than those from Ontario because of the large
number of exposed cases. The association we found between
any current exposure to antidepressants and postpartum
hemorrhage was similar to the association between
antidepressants prescribed during antenatal care and bleeding
during delivery reported by Reis and colleagues.20We attempted
to reduce potential confounding by factors associated with
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underlyingmood/anxiety disorders by restriction to womenwith
diagnoses of mood/anxiety disorder, adjusting for proxies of
severity of indication, and using high dimensional propensity
score analysis whereas previous studies did not.
Possible explanations of results
We found no evidence that the delivery characteristics mediated
the association. Along with cofactors, serotonin contributes to
platelet aggregation, and the association between serotonin
reuptake inhibitor and bleeding could be explained, at least in
part, by the inhibition of serotonin reuptake by platelets, which
cannot synthesize serotonin.15 Normally, excessive uterine
bleeding from the site of placental implantation is prevented by
uterine myometrial contraction.25 Serotonin reuptake inhibitors
increase extracelluar serotonin concentrations,48 and the
myometrium contracts in response to serotonin.49 Besides
interfering with hemostasis, serotonin reuptake inhibitors could
also interfere with serotonin mediated uterine contraction and
contribute to atonic postpartum hemorrhage.
When we consider the hypothesis that the risk of bleeding
increases with exposure to antidepressants that block serotonin
reuptake,50 the association between non-serotonin reuptake
inhibitor monotherapy and postpartum hemorrhage is
unexpected. The positive associations between both serotonin
and non-serotonin reuptake inhibitors and postpartum
hemorrhage could indicate that all antidepressants impact on
risk of postpartum hemorrhage. We cannot rule out the
possibility, however, that the results are confounded by
unmeasured factors associated with the underlying disorders.
While we did not hypothesize it a priori, it is possible that
non-serotonin reuptake inhibitors could affect postpartum
hemorrhage through pathways other than those potentially
mediated by serotonin reuptake inhibition. Trazodone, a
non-serotonin reuptake inhibitor, is a 5-HT2A receptor
antagonist26 and serotonin induced myometrial contraction is
mediated by this receptor,49 consequently blockade of the 5-HT2A
receptor could explain an association between trazodone use
and atonic postpartum hemorrhage. It is possible that some of
the positive findings are caused by chance. Overall, monotherapy
with a non-serotonin reuptake inhibitor was rare in the cohort,
comprising only 12.1% of antidepressant users. The results for
non-serotonin reuptake inhibitors were much less precise than
those for serotonin reuptake inhibitors, and some of the
sensitivity analyses attenuated results toward the null,
particularly for past use of non-serotonin reuptake inhibitors.
It is possible that we failed to control for confounders that were
particularly important among this group of women such as
alcohol abuse or smoking. Bupropion, which is also indicated
for smoking cessation,51 accounted for nearly 80% of current
use of non-serotonin reuptake inhibitors. It is unclear, however,
whether smoking is positively associated with postpartum
hemorrhage.43 52 53
Potential limitations
Though adjustment for many measured potential confounders
with standard multivariable regression and high dimensional
propensity score analysis did not affect the results, the
associations could reflect unmeasured confounding. Because
the use of many antidepressants, not just serotonin reuptake
inhibitors, near the time of delivery was associated with
postpartum hemorrhage, it is possible that our results could
potentially reflect residual confounding by unmeasured
behavioral factors associated with depression and antidepressant
use. These factors include inadequate diet and the use of tobacco,
alcohol, and illegal drugs,54 55 which are inadequately captured
by data on healthcare use. Although mood/anxiety disorders
were not strongly associated with postpartum hemorrhage, it is
possible that the unmeasured factors that are associated with
the severity of the disorder could have confounded the results.
Based on external adjustment, our results could have been
attenuated slightly had we been able to adjust for body mass
index (BMI). Residual confounding by use of over the counter
aspirin is probably small, given the expected low prevalence of
use in the third trimester.56Misclassification of exposure is also
a potential limitation because we cannot confirm that women
were taking antidepressants on the days we assumed.57 No
information was available regarding antidepressant use during
admission to hospital, including the admission for delivery. We
expect that this had a minimal impact on the misclassification
of antidepressant use near the time of delivery because 95% of
women delivered within one day of being admitted to hospital.
Misclassification would be non-differential and would tend to
attenuate the true association. The result including only women
with the greatest amount of antidepressant coverage in the 90
days before delivery in the current exposure groups is reassuring
because they were less likely to be affected bymisclassification
as these women were likely to have been taking antidepressants
near the time of delivery. Furthermore, we did not have adequate
power to examine the association between antidepressants and
severe postpartum hemorrhage leading to blood transfusion or
mortality. Finally, outcome misclassification is another source
of bias, which would likely result in an underestimation of a
true association. The following support the validity of the
outcome definition. The positive predictive value for postpartum
hemorrhage was 85% based on ICD-9 codes 666.0x-666.2x in
discharge data from California hospitals.58 The magnitudes of
association between well established risk factors for postpartum
hemorrhage and postpartum hemorrhage were similar to those
reported in previous studies.6 7 30 31 Moreover, the risk of
postpartum hemorrhage was in line with US national statistics.5
Generalizability of results
This study was conducted among women enrolled in the US
Medicaid program, which covers the healthcare of 40% of all
pregnant women with deliveries in the US.59 Women in the
cohort were low income, tended to be younger, and were more
likely to be black compared with national figures for pregnant
women.60 Nonetheless, the baseline risk of postpartum
hemorrhage in our population was 2.9%, which is similar to
that of the general US population5 but lower than the risks
reported for Canada and Australia.8Results suggested that there
was no association with non-serotonin reuptake inhibitors in
older women. Because of the small numbers, however, this
should be confirmed in another study. Furthermore, we found
no evidence of effect modification by race or ethnicity. Based
on these findings, we anticipate that the results will apply to
other populations with a similar baseline risk for postpartum
hemorrhage.
Conclusions
This study is the first to report an association between exposure
to antidepressants at the time of delivery and risk of postpartum
hemorrhage in a US population and in a population with a
diagnosis of depression. The large study size permitted us to
consider specific antidepressants, yet, despite the large cohort,
there were still too few women with postpartum hemorrhage
exposed to certain antidepressants, including trazodone and
mirtazapine, to produce stable estimates. Also, the large size
allowed us to define the primary exposure window as the
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delivery date, rather than using a wide window to gain enough
cases for precise estimates, which can bias results downward.
Our study suggests that all classes of antidepressants are
associated with an increased risk for abnormal bleeding. The
magnitudes of association were in the range of those previously
reported from Canadian and Swedish populations,19 20 and we
found that serotonin norepinephrine reuptake inhibitors and
tricyclics were also associated with increased risk. Our findings
regarding non-serotonin reuptake inhibitor antidepressants were
unexpected and should be confirmed. Additional studies that
account for clinical measures of severity of depression and
behavioral factors associated with antidepressant use near the
end of pregnancy are warranted to rule out the possibility that
the associations with serotonin and non-serotonin reuptake
inhibitors reflect confounding. Although we cannot rule out
residual confounding, our study indicates that there might be
about one excess case of postpartum hemorrhage for every 80
to 100 women using antidepressants near the time of delivery,
if we assume causality. The absolute increase in risk associated
with antidepressant exposure in the month before delivery is
small, but women and their physicians should be aware of the
potential risks when making treatment decisions near the end
of pregnancy.
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Tables
Table 1| Characteristics of pregnant women by exposure to antidepressants in US Medicaid Analytic eXtract. Figures are numbers
(percentage) unless stated otherwise
Non-SRI monotherapy (n=4456)SRI monotherapy (n=29 222)
Unexposed
(n=69 044)Covariates Past (n=2132)Recent (n=829)Current (n=1495)Past (n=10 416)Recent (n=6096)
Current (n=12
710)
Birth year:
399 (18.7)141 (17.0)242 (16.2)2180 (20.9)1324 (21.7)2780 (21.9)16 310 (23.6)2000-02
588 (27.6)235 (28.4)403 (27.0)3367 (32.3)1966 (32.3)4382 (34.5)18 850 (27.3)2003-04
1145 (53.7)453 (54.6)850 (56.9)4869 (46.8)2806 (46.0)5548 (43.7)33 884 (49.1)2005-07
Region:
257 (12.1)108 (13.0)198 (13.2)1340 (12.9)844 (13.9)1931 (15.2)10 884 (15.8)Northeast
737 (34.6)254 (30.6)438 (29.3)3287 (31.6)1793 (29.4)3237 (25.5)20 712 (30.0)South
822 (38.6)343 (41.4)612 (40.9)4345 (41.7)2533 (41.65448 (42.9)24 729 (35.8)Midwest
316 (14.8)124 (15.0)247 (16.5)1444 (13.9)926 (15.2)2094 (16.5)12 719 (18.4)West
24 (21-28)25 (21-29)26 (22-31)24 (21-28)24 (21-29)25 (22-30)23 (20-27)Median (IQR) age (years)
Race:
1546 (72.5)601 (72.5)1198 (80.1)7149 (68.6)4471 (73.3)10 103 (79.5)40 543 (58.7)White
335 (15.7)111 (13.4)136 (9.1)1787 (17.2)801 (13.1)1027 (8.1)15 522 (22.5)Black
130 (6.1)61 (7.4)65 (4.4)813 (7.8)467 (7.7)776 (6.1)8312 (12.0)Hispanic
121 (5.7)56 (6.8)96 (6.4)667 (6.4)357 (5.9)804 (6.3)4667 (6.8)Other or unknown
39 (1.8)19 (2.3)36 (2.4)213 (2.0)113 (1.9)218 (1.7)1275 (1.9)Multiple pregnancy
219 (10.3)76 (9.2)152 (10.2)930 (8.9)678 (11.1)1392 (11.0)5557 (8.1)Diabetes diagnosis or
dispensing of antidiabetic
116 (5.4)47 (5.7)89 (6.0)588 (5.7)373 (6.1)800 (6.3)2694 (3.9)Hypertension diagnosis or
dispensing of
antihypertensive
17 (0.8)——95 (0.9)47 (0.8)99 (0.8)440 (0.6)Coagulopathy*
175 (8.2)75 (9.1)115 (7.7)960 (9.2)631 (10.4)1077 (8.5)3321 (4.8)Any inpatient
mood/anxiety disorder
diagnosis
2 (1-4)2 (1-5)2 (1-5)2 (1-4)2 (1-4)2 (1-4)2 (1-4)Median (IQR) No of
mood/anxiety diagnoses
Other indications for antidepressant use:
39 (1.8)11 (1.3)28 (1.9)187 (1.8)98 (1.6)176 (1.4)808 (1.2)Psychotic disorder
92 (4.3)37 (4.5)70 (4.7)510 (4.9)294 (4.8)553 (4.4)2659 (3.9)Other mental health
disorder
111 (5.2)38 (4.6)75 (5.0)624 (6.0)332 (5.5)705 (5.6)2109 (3.1)Pain related condition
47 (2.2)16 (1.9)17 (1.1)124 (1.2)72 (1.2)151 (1.2)390 (0.6)Sleep disorder
Other drug use at baseline:
57 (2.7)34 (4.1)68 (4.6)288 (2.8)191 (3.1)463 (3.6)1008 (1.5)Anticonvulsants
219 (10.3)77 (9.3)166 (11.1)950 (9.1)606 (9.9)1351 (10.6)2330 (3.4)Benzodiazepines
13 (0.6)——43 (0.4)20 (0.3)32 (0.3)141 (0.2)Aspirin*
———40 (0.4)26 (0.4)39 (0.3)175 (0.3)Heparin*
———54 (0.5)26 (0.4)69 (0.5)267 (0.4)Low molecular weight
heparin*
———————Warfarin*
15 (11-20)15 (11-20)15 (11-20)14 (11-19)14 (11-19)14 (11-20)14 (11-19)Median (IQR) No of
baseline outpatient visits
308 (14.5)114 (13.8)191 (12.8)1633 (15.7)965 (15.8)1743 (13.7)7426 (10.8)Any admissions to
hospital during baseline
Delivery characteristics:
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Table 1 (continued)
Non-SRI monotherapy (n=4456)SRI monotherapy (n=29 222)
Unexposed
(n=69 044)Covariates Past (n=2132)Recent (n=829)Current (n=1495)Past (n=10 416)Recent (n=6096)
Current (n=12
710)
1952 (91.6)748 (90.2)1370 (91.6)9452 (90.8)5622 (92.2)11 594 (91.2)62 351 (90.3)In hospital
1858 (95.2)705 (94.3)1304 (95.2)8940 (94.6)5292 (6.0)1107 (95.8)59 400 (95.8)Delivery within 1 day of
admission†
52 (2.4)15 (1.8)54 (3.6)305 (2.9)180 (3.0)423 (3.3)1724 (2.5)Short labor
51 (2.4)18 (2.2)30 (2.0)233 (2.2)146 (2.4)303 (2.4)1620 (2.4)Long labor
301 (14.1)98 (11.8)210 (14.1)1332 (12.8)774 (12.7)1530 (12.0))8422 (12.2)Labor induction
103 (4.8)37 (4.5)70 (4.7)556 (5.3)332 (5.5)729 (5.7)3913 (5.7)Forceps or vacuum
delivery
IQR=interquartile range; SRI=serotonin reuptake inhibitor.
*Cell sizes too small for display per Centers for Medicare and Medicaid Services cell size suppression policy.
†Excludes women who delivered outside hospital.
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Table 2| Relative risks (RR) and 95% confidence intervals (CI) comparing risk for postpartum hemorrhage in pregnant women exposed to
antidepressants
RR (95% CI)No (%) of women with
postpartum hemorrhageTotalExposure Group Fully adjusted†Adjusted for delivery year*
SRI monotherapy:
1.47 (1.33 to 1.62)1.44 (1.30 to 1.58)503 (4.0)12710Current
1.19 (1.03 to 1.38)1.17 (1.01 to 1.35)196 (3.2)6096Recent
0.93 (0.82 to 1.06)0.92 (0.81 to 1.05)264 (2.5)10416Past
Non-SRI monotherapy:
1.39 (1.07 to 1.81)1.36 (1.05 to 1.77)56 (3.8)1495Current
1.17 (0.80 to 1.70)1.15 (0.79 to 1.68)26 (3.1)829Recent
1.26 (1.00 to 1.59)1.24 (0.99 to 1.56)73 (3.4)2132Past
ReferenceReference1896 (2.8)69044Unexposed
SRI=serotonin reuptake inhibitors.
*2000-01, 2002, 2003, 2004, 2005, 2006, 2007.
†Delivery year, age, race, multiple pregnancy, diabetes, coagulopathy, number of outpatient mood/anxiety disorder diagnoses, number of inpatient mood/anxiety
disorder diagnoses, psychotic disorder, other mental health disorder, pain indication, sleep disorder, anticonvulsant dispensing, benzodiazepine dispensing, aspirin
dispensing, heparin dispensing, low molecular weight heparin dispensing, warfarin dispensing, and number of outpatient visits and days in hospital during baseline.
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Table 3| High dimensional propensity score analysis*. Figures are odds ratios and 95% confidence intervals adjusted for 10ths of propensity
score, comparing risk for postpartum hemorrhage in pregnant women with current antidepressant exposure
Covariates in propensity score modelNo (%) of women with
postpartum
hemorrhageTotal†
Investigator defined‡ and
empirically definedInvestigator defined‡Delivery year
1.52 (1.35 to 1.71)1.47 (1.32 to 1.64)1.46 (1.32 to 1.61)415 (4.1)10 203SRI monotherapy
ReferenceReferenceReference1479 (2.8)53 348Unexposed
1.39 (1.03 to 1.89)1.49 (1.12 to 1.98)1.39 (1.06 to 1.82)45 (3.9)1162Non-SRI monotherapy
ReferenceReferenceReference1475 (2.8)52192Unexposed
SRI=serotonin reuptake inhibitor.
*Women with highest and lowest 2.5% of propensity score excluded from analyses.
†Numbers are for trimmed population in investigator defined and empirically defined covariates analysis.
‡Investigator defined covariates: delivery year, age, race, multiple pregnancy, diabetes, coagulopathy, number of outpatient mood/anxiety disorder diagnoses,
number of inpatient mood/anxiety disorder diagnoses, psychotic disorder, other mental health disorder, pain indication, sleep disorder, anticonvulsant dispensing,
benzodiazepine dispensing, aspirin dispensing, heparin dispensing, low molecular weight heparin dispensing, and number of outpatient visits and days in hospital
during baseline.
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Table 4| Fully adjusted* relative risks (RR) and 95% confidence intervals (CI) comparing risk for postpartum hemorrhage by specific
antidepressants; restricted to women with serotonin reuptake inhibitor (SRI) or non-SRI monotherapy
RR (95% CI)
No (%) of women with postpartum
hemorrhageTotalSpecific antidepressants
Paroxetine:
1.36 (1.09 to 1.71)77 (3.8)2055Current
1.52 (1.12 to 2.07)40 (4.2)962Recent
1.13 (0.85 to 1.49)49 (3.0)1617Past
Sertraline:
1.31 (1.12 to 1.54)162 (3.6)4526Current
1.27 (1.01 to 1.59)78 (3.4)2266Recent
0.82 (0.66 to 1.01)85 (2.2)3812Past
Fluoxetine:
1.51 (1.27 to 1.79)137 (4.1)3322Current
1.14 (0.86 to 1.50)50 (3.1)1628Recent
0.93 (0.75 to 1.17)78 (2.5)3075Past
Escitalopram:
1.56 (1.16 to 2.09)43 (4.2)1022Current
1.01 (0.61 to 1.70)14 (2.7)520Recent
0.96 (0.64 to 1.42)24 (2.6)940Past
Citalopram:
1.48 (1.07 to 2.04)36 (4.0)891Current
0.70 (0.37 to 1.34)—462Recent†
0.76 (0.47 to 1.23)17 (2.1)830Past
Amitriptyline:
1.68 (0.89 to 3.16)—176Current†
1.13 (0.29 to 4.42)—69Recent†
1.08 (0.48 to 2.42)—206Past†
Venlafaxine:
2.24 (1.69 to 2.97)46 (6.0)763Current
1.10 (0.53 to 2.30)—237Recent†
0.98 (0.56 to 1.70)12 (2.6)458Past
Trazodone:
1.85 (0.90 to 3.80)—139Current†
2.01 (0.77 to 5.24)—73Recent†
0.61 (0.23 to 1.67)—226Past†
Bupropion:
1.32 (0.98 to 1.79)42 (3.6)1162Current
1.17 (0.77 to 1.79)21 (3.2)660Recent
1.32 (1.02 to 1.69)61 (3.6)1712Past
Mirtazapine:
0.87 (0.29 to 2.66)—129Current†
—057Recent
1.07 (0.40 to 2.82)—135Past†
Reference1896 (2.8)69 044No exposure
*Delivery year, age, race, multiple pregnancy, diabetes, coagulopathy, number of mood/anxiety disorder diagnoses, number of inpatient mood/anxiety disorder
diagnoses, psychotic disorder, other mental health disorder, pain indication, sleep disorder, anticonvulsant dispensing, benzodiazepine dispensing, aspirin
dispensing, heparin dispensing, low molecular weight heparin dispensing, number of outpatient visits and days in hospital during baseline, and for other specific
antidepressants within each time period, including those listed above and clomipramine, duloxetine, imipramine, nortriptyline, doxepin, and nefazodone.
†Cell sizes are too small for display per Centers for Medicare and Medicaid Services cell size suppression policy.
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Table 5 Fully adjusted* relative risks (RR) and 95% confidence intervals (CI) comparing risk for postpartum hemorrhage in pregnant women
with exposure to antidepressants by alternative exposure groups
RR (95% CI)
No (%) of women with postpartum
hemorrhageTotal
All antidepressants:
1.44 (1.32 to 1.58)620 (3.9)16 029Current
1.21 (1.06 to 1.38)247 (3.3)7577Recent
0.98 (0.88 to 1.10)357 (2.7)13 350Past
Antidepressant classes
SSRI monotherapy:
1.42 (1.27 to 1.57)440 (3.8)11 516Current
1.21 (1.04 to 1.40)186 (3.3)5706Recent
0.93 (0.81 to 1.06)244 (2.5)9675Past
SNRI monotherapy:
1.90 (1.37 to 2.63)35 (5.0)702Current
1.21 (0.58 to 2.54)—217Recent†
1.05 (0.60 to 1.83)12 (2.8)423Past
Tricyclic monotherapy:
1.77 (0.90 to 3.47)—175Current†
0.51 (0.08 to 3.40)—75Recent†
1.37 (0.72 to 2.61)—245Past†
Bupropion monotherapy:
1.32 (0.97 to 1.80)40 (3.6)1114Current
1.20 (0.79 to 1.83)21 (3.2)649Recent
1.33 (1.03 to 1.71)60 (3.6)1666Past
Other monotherapy:
1.37 (0.72 to 2.60)—251Current†
1.13 (0.43 to 2.95)—134Recent†
0.85 (0.42 to 1.71)—344Past†
Reference1896 (2.8)69 044Unexposed
*Delivery year, age, race, multiple pregnancy, diabetes, coagulopathy, number of outpatient mood/anxiety disorder diagnoses, number of inpatient mood/anxiety
disorder diagnoses, psychotic disorder, other mental health disorder, pain indication, sleep disorder, anticonvulsant dispensing, benzodiazepine dispensing, aspirin
dispensing, heparin dispensing, low molecular weight heparin dispensing, warfarin dispensing, and number of outpatient visits and days in hospital during baseline.
†Cell sizes too small for display per Centers for Medicare and Medicaid Services cell size suppression policy.
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Table 6| Fully adjusted* relative risks (RR) and 95% confidence intervals (CI) comparing risk for postpartum hemorrhage among pregnant
women with current exposure by dose†
RR (95% CI)
No (%) of women with postpartum
hemorrhageTotal
SRI monotherapy:
1.55 (1.21 to 1.97)66 (4.1)1597High
1.51 (1.34 to 1.70)324 (4.1)7877Medium
1.29 (1.07 to 1.55)113 (3.5)3236Low
Non-SRI monotherapy:
1.07 (0.61 to 1.88)12 (2.9)419Medium or high
1.49 (1.11 to 2.00)44 (4.1)1074Low
Reference1896 (2.8)69 044Unexposed
SRI=serotonin reuptake inhibitor.
*Delivery year, age, race, multiple pregnancy, diabetes, coagulopathy, number of outpatient mood/anxiety disorder diagnoses, number of inpatient mood/anxiety
disorder diagnoses, psychotic disorder, other mental health disorder, pain indication, sleep disorder, anticonvulsant dispensing, benzodiazepine dispensing, aspirin
dispensing, heparin dispensing, low molecular weight heparin dispensing, and number of outpatient visits and days in hospital during baseline.
†Dose levels were defined according to Goodman &Gilman’s usual dose (mg/day):26 low <lowest usual dose, medium ≤midpoint of usual dose range, high >midpoint
of usual dose range.
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Figures
Fig 1 Timeline of study. Months are before delivery date (for example, −5 months is 5 months before delivery date)
Fig 2 Primary and sensitivity analyses with adjusted relative risks and 95% confidence intervals comparing risk for postpartum
hemorrhage (PPH) in women with exposure to antidepressants (AD) in pregnancy. *Odds ratios estimated without adjustment
for correlation among multiple pregnancies in same women because of computing limitations. †Restricted to women who
had mood/anxiety disorders and met Medicaid enrollment and eligibility requirements throughout pregnancy
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